p. 1−11
2314-8756
Vol.1.1/No.1
20 years old, and those >40 years old had significantly more anti-HAV IgG seropositivity compared to those who are younger in age (OR: 11.4, 95% CI 4.8-27; p<0.0001 and OR: 3.8, 95% CI 1.7-8.6; p<0.01 respectively). Conclusions: Only 30% of CLD patients are tested for HAV serology, 17% of them are susceptible to HAV infection especially those who areyounger and with non-viral etiology. Detection and vaccination of these subgroups is warranted to avoid superinfection with HAV. ]]>
p. 1−9
2314-8756
Vol.1.1/No.1
p. 1−9
2314-8756
Vol.1.1/No.1
2000 iu/mL or >20000 iu/mL accordingto HBeAg status) and ALT level >2x40 u/L (the standard cut-off value), only 36/161(22.4 %) patients were candidate for therapy. This increased to 71/161(44.1 %) patients when the new ALT cut-off values (30 u/L for males, and 19 u/L for females) were applied. Relying on either (F≥2 and/or A≥2) or (F≥2±A≥2) increases the treatment candidacy by 62/161(38.5 %) or 45/161(28 %), and further increases the candidacy for treatment by 27/161(16.8 %) or 10/161(6.2 %) patients when standard and new ALT cut-off values are applied respectively. Finally, liver histopathology is more reliable than ALT and HBV-DNA levels in the decision to treat patients with chronic HBV infection.]]>
p. 1−14
2314-8756
Vol.1.1/No.1